You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Veracyte Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Veracyte Company Info
Veracyte Inc is engaged in the discovery, development, and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.
News & Analysis
Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.
Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.
This genetic diagnostics company could be a good pick for growth investors.
Veracyte has sharply rebounded from the COVID-19 headwinds that it faced last year and should continue growing.
Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.
Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.
Genome testing is exploding on a global level; these companies are saving lives and making money.
The genomic test maker posted a mighty fine third quarter.
VCYT earnings call for the period ending March 31, 2020.
VCYT earnings call for the period ending December 31, 2019.
VCYT earnings call for the period ending September 30, 2019.
VCYT earnings call for the period ending June 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.